by Chris Woolstenhulme, QCC, CMCS, CPC, CMRS
April 20th, 2017
When billing dermal filler injections, separate payment may be made under the OPPS and ASC payment systems for HCPCS G0429- Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy).
Use in addition: Q2026- Injection, radiesse, 0.1 ml, and Q2028 - Injection, sculptra, 0.5 mg
With a diagnosis of B20 - Human immunodeficiency virus [HIV] disease or E88.1 - Lipodystrophy, not elsewhere classified.
References:
Billing Dermal Filler Injections. (2017, April 20). Find-A-Code Spotlight. Retrieved from https://www.findacode.com/articles/billing-dermal-filler-injections-31529.html
© 2017 innoviHealth Systems (Find-A-Code)
Publish this Article on your Website, Blog or Newsletter
This article is available for publishing on websites, blogs, and newsletters. The article must be published in its entirety - all links must be active. If you would like to publish this article, please contact us and let us know where you will be publishing it. The easiest way to get the text of the article is to highlight and copy. Or use your browser's "View Source" option to capture the HTML formatted code.
If you would like a specific article written on a medical coding and billing topic, please Contact Us.
Quick, Current, Complete - www.findacode.com